Note in the Associate Press report today on Merck’s 2Q earnings…
nytimes.com/2013/07/31/busin … .html?_r=0
…this passage:
"[Merck] has been hurt by plunging sales not just for its former top seller, the asthma and allergy medication Singulair, but also the migraine drug Maxalt, the baldness treatment Propecia and the allergy pill Clarinex.
“Merck said its second-quarter net income was $906 million, or 30 cents a share, compared with $1.79 billion, or 58 cents a share, a year earlier.”